Penumbra (PEN) Q1 Earnings and Revenues Top Estimates

Core Viewpoint - Penumbra reported quarterly earnings of $0.83 per share, exceeding the Zacks Consensus Estimate of $0.66 per share, and showing a significant increase from $0.41 per share a year ago, representing an earnings surprise of 25.76% [1][2] Financial Performance - The company achieved revenues of $324.14 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.67% and increasing from $278.66 million year-over-year [2] - Over the last four quarters, Penumbra has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Penumbra shares have increased approximately 16.7% since the beginning of the year, contrasting with a decline of -10.1% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.84, with projected revenues of $331.44 million, and for the current fiscal year, the EPS estimate is $3.64 on revenues of $1.35 billion [7] - The outlook for the Medical - Instruments industry is positive, ranking in the top 35% of over 250 Zacks industries, suggesting potential for outperformance [8]